LT-002-158 / Shanghai Leadingtac Pharma - LARVOL DELTA

A Single and Multiple Ascending Dose Trial of LT-002-158 Tablets in Healthy Adult Volunteers (clinicaltrials.gov) - P1 | N=150 | Completed | Sponsor: Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | Recruiting ➔ Completed | Trial completion date: Jun 2025 ➔ Nov 2025 | Trial primary completion date: Mar 2025 ➔ Nov 2025

First-in-human • Trial completion • Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Hidradenitis Suppurativa • Immunology

A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Patients With Hidradenitis Suppurativa (clinicaltrials.gov) - P1/2 | N=12 | Recruiting | Sponsor: Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2025 ➔ Dec 2028 | Trial primary completion date: Oct 2025 ➔ Oct 2028

Enrollment open • Trial completion date • Trial primary completion date • Dermatology • Hidradenitis Suppurativa • Immunology

A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Subjects With Atopic Dermatitis (clinicaltrials.gov) - P1/2 | N=24 | Recruiting | Sponsor: Leadingtac Pharmaceutical (Shaoxing) Co., Ltd. | Not yet recruiting ➔ Recruiting | Trial completion date: Dec 2025 ➔ Mar 2028 | Trial primary completion date: Oct 2025 ➔ Feb 2028

Enrollment open • Trial completion date • Trial primary completion date • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Subjects With Atopic Dermatitis (clinicaltrials.gov) - P1/2 | N=24 | Not yet recruiting | Sponsor: Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.

New P1/2 trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology

A Study to Explore the Safety, Tolerability, Efficacy, and Pharmacokinetics of LT-002-158 Tablets in Chinese Adult Patients With Hidradenitis Suppurativa (clinicaltrials.gov) - P1/2 | N=12 | Not yet recruiting | Sponsor: Leadingtac Pharmaceutical (Shaoxing) Co., Ltd.

New P1/2 trial • Dermatology • Hidradenitis Suppurativa • Immunology

A Single and Multiple Ascending Dose Trial of LT-002-158 Tablets in Healthy Adult Volunteers (clinicaltrials.gov) - P1 | N=127 | Recruiting | Sponsor: Shanghai Leadingtac Pharmaceutical Co., Ltd. | N=82 ➔ 127

Enrollment change • Atopic Dermatitis • Dermatitis • Dermatology • Hidradenitis Suppurativa • Immunology

A Single and Multiple Ascending Dose Trial of LT-002-158 in Healthy Adult Volunteers (clinicaltrials.gov) - P1 | N=82 | Recruiting | Sponsor: Shanghai Leadingtac Pharmaceutical Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Atopic Dermatitis • Dermatitis • Dermatology • Hidradenitis Suppurativa • Immunology

A Single and Multiple Ascending Dose Trial of LT-002-158 in Healthy Adult Volunteers (clinicaltrials.gov) - P1 | N=82 | Not yet recruiting | Sponsor: Shanghai Leadingtac Pharmaceutical Co., Ltd. | Initiation date: Jan 2024 ➔ Jun 2024

Trial initiation date • Atopic Dermatitis • Dermatitis • Dermatology • Hidradenitis Suppurativa • Immunology

A Phase 1 Study of LT-002-158 Intended for the Treatment of Skind Disorder in Healthy Adult Volunteers (clinicaltrials.gov) - P1 | N=78 | Not yet recruiting | Sponsor: Shanghai Leadingtac Pharmaceutical Co., Ltd.

New P1 trial • Atopic Dermatitis • Dermatitis • Dermatology • Hidradenitis Suppurativa • Immunology